Niacin 100 mg by Vitamer Laboratories — Ingredients, Evidence & Safety

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Niacin: 100mg is 2.9× the Tolerable Upper Intake Level (35mg)

The safety score is low because the 100mg dose of niacin is nearly three times higher than the recommended maximum daily limit of 35mg.

Label Data

1 Tablet(s) Serving Size

100 Servings

Vitamin Product Type

100% Evidence Coverage

Supplement Facts — Evidence Check

Niacin

100 mg (500% DV)

⚠️ Exceeds Tolerable Upper Intake Level by 2.9× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)

RDA 14mg This product: 100mg UL 35mg

Other Ingredients

Cellulose Silica Stearic Acid Calcium Stearate

Label Claims — Verification

❓ All Other

❓ Structure/Function

All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Vegan Vegetarian Adult (18 - 50 Years) Gluten Free Dairy Free

Product Information

📋 Directions for Use

SUGGESTED USE: Take one tablet daily with food.

⚠️ Warnings & Precautions

KEEP OUT OF REACH OF CHILDREN.

🧪 Formulation Notes

CONTAINS NO artificial colors, flavors or preservatives; no wheat, gluten, milk, eggs, peanuts, tree nuts, soy, crustacean shellfish or fish.

Suitable for vegans.

Suitable for vegetarians and non-vegetarians alike, these tablets are from a non-animal source.

Additional Information

One of the B Vitamins, Niacin promotes healthy cholesterol levels and supports energy production.

WE GUARANTEE OUR SUPPLEMENTS FOR POTENCY AND PURITY

Essential for Energy Production

DOUBLE VERIFIED GLUTEN FREE(R)

VL 222-100L

Product Details

UPC / SKU 7 19985 22240 5

DSLD Entry Date 2013-09-25

Product Type Vitamin

Form Tablet or Pill

Brand Vitamer Laboratories

DSLD ID 23357

Data Updated 2026-04-11

Research Evidence

241 Research Sources

55 Avg Quality Score

113 Meta Analysis

75 Systematic Review

32 Rct

11 Clinical Trial

3 Other

3 Regulatory Source

1 Cochrane Review

1 Narrative Review

1 Openfda Safety

A Niacin for primary and secondary prevention of cardiovascular events

Meta Analysis The Cochrane database of systematic reviews 2017

PubMed DOI Cochrane

A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases

Meta Analysis BMJ (Clinical research ed.) 2013

PubMed DOI

A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients

Meta Analysis BMJ (Clinical research ed.) 2014

PubMed DOI

A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk

Meta Analysis Nature medicine 2024

PubMed DOI

A Meta-analysis and imputation refines the association of 15q25 with smoking quantity

Meta Analysis Nature genetics 2010

PubMed DOI

A Genome-wide meta-analyses identify multiple loci associated with smoking behavior

Meta Analysis Nature genetics 2010

PubMed DOI

A Antidepressants for smoking cessation

Meta Analysis The Cochrane database of systematic reviews 2014

PubMed DOI

A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne

Meta Analysis The Cochrane database of systematic reviews 2020

PubMed DOI Cochrane

B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis

Meta Analysis JAMA network open 2019

PubMed DOI

B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis

Meta Analysis JAMA 2016

PubMed DOI

View all evidence for Niacin →